Lowering the Bar

Littlehales, Crispin
April 2007
Red Herring;4/30/2007, Vol. 4 Issue 16, p28
Trade Publication
The article reports that the U.S. National Cancer Institute, along with the pharmaceutical and biotechnology industries and numerous foundations, have invested an estimated $80 billion to $100 billion on research worldwide, since it declared war on cancer 36 years ago. But cancer research on improving existing drug lines and advances in slow-release medications and blending drugs to make them easier for patients to use have all helped but only incrementally, according to Julian Adams, chief scientific officer and president of Cambridge, Massachusetts-based Infinity Pharmaceuticals.


Related Articles

  • Breast International Group (BIG).  // Annals of Oncology;May2014 Supplement 1, Vol. 25 Issue suppl_1, pv 

    No abstract available.

  • EORTC-NCI-AACR ROUNDUP.  // BioWorld Today;10/24/2008, Vol. 19 Issue 208, p9 

    This article offers a summary of data presented at the European Organization for Research and Treatment of Cancer (EORTC) in conjunction with the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics in...

  • Laetrile Flunks.  // Time; 

    The article discusses the results of the tests conducted by U.S. National Cancer Institute involving laetrile for the treatment of cancer. The tests were done on 156 patients with advanced cancer from four hospitals including Mayo Clinic in Rochester, Minnesota, Memorial Sloan-Kettering Cancer...

  • Cancer Is Genetically Diverse, But Cancer Cell Lines Are Not. Breindl, Anette // BioWorld Today;11/2/2011, Vol. 22 Issue 213, p1 

    The article presents the results of a study conducted by scientists at the National Cancer Institute on the reasons why cancer is difficult to treat. Michael Gottesman, senior author of the study, explained that the variation of genetic alterations contributed to the difficulty of treating...

  • Intergroup Phase III Study (CALGB 100104) Reports Overall Survival Benefit with Revlimid(r) As Continuous Therapy for Patients with Multiple Myeloma.  // Biomedical Market Newsletter;5/9/2011, p222 

    The article cites a clinical study sponsored by the U.S. National Cancer Institute, presented by representatives led by the Cancer and Leukemia Group B (CALGB) at the 2011 International Myeloma Workshop in Paris, France. The Intergroup Phase III Study reports overall survival benefit with...

  • Adult Cancer Clinical Trials That Fail to Complete: An Epidemic? Stensland, Kristian D.; McBride, Russell B.; Latif, Asma; Wisnivesky, Juan; Hendricks, Ryan; Roper, Nitin; Boffetta, Paolo; Hall, Simon J.; Oh, William K.; Galsky, Matthew D. // JNCI: Journal of the National Cancer Institute;Sep2014, Vol. 106 Issue 9, p1 

    The number and diversity of cancer therapeutics in the pipeline has increased over the past decade due to an enhanced understanding of cancer biology and the identification of novel therapeutic targets. At the same time, the cost of bringing new drugs to market and the regulatory burdens...

  • A Shot at Cancer. Park, Alice // Time International (South Pacific Edition);9/14/2009, Vol. 174 Issue 10, p26 

    The article discusses the continuing medical battle against cancer, historical treatment approaches, and growth in the use of vaccines to prevent relapses after other treatments are complete. It discusses the work of National Cancer Institute (NCI) medical researchers Douglas Schwartzentruber...

  • AACR Roundup.  // BioWorld Today;11/17/2011, Vol. 22 Issue 224, p8 

    The article reports on data presented at the American Association for Cancer Research (AACR)-National Cancer Institute (NCI)- European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.

  • FIGHTING CANCER FROM WITHIN. Lemonick, Michael D. // Time;9/30/2002, Vol. 160 Issue 14, p63 

    Reports on a cancer-fighting technique that was announced in 'Science.' Use of the immune system in the body against cancer; Research conducted at the National Cancer Institute; T-cell injections; Tumor shrinkage.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics